DE69316660T3 - Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten - Google Patents

Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten

Info

Publication number
DE69316660T3
DE69316660T3 DE1993616660 DE69316660T DE69316660T3 DE 69316660 T3 DE69316660 T3 DE 69316660T3 DE 1993616660 DE1993616660 DE 1993616660 DE 69316660 T DE69316660 T DE 69316660T DE 69316660 T3 DE69316660 T3 DE 69316660T3
Authority
DE
Grant status
Grant
Patent type
Prior art keywords
terfanadin
metabolites
optically pure
allergic diseases
pure isomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE1993616660
Other languages
English (en)
Other versions
DE69316660T2 (de )
DE69316660D1 (de )
Inventor
James Young
Nancy Gray
Raymond Woosley
Yiwang Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date
Family has litigation

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
DE1993616660 1992-08-03 1993-08-03 Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten Expired - Lifetime DE69316660T3 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US92418292 true 1992-08-03 1992-08-03
US92415692 true 1992-08-03 1992-08-03
PCT/US1993/007260 WO1994003170A1 (en) 1992-08-03 1993-08-03 Terfenadine metabolites and their optically pure isomers for treating allergic disorders

Publications (2)

Publication Number Publication Date
DE69316660T2 DE69316660T2 (de) 1998-05-07
DE69316660T3 true DE69316660T3 (de) 2001-04-05

Family

ID=27129882

Family Applications (8)

Application Number Title Priority Date Filing Date
DE1993616660 Expired - Lifetime DE69316660D1 (de) 1992-08-03 1993-08-03 Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten
DE1993634145 Expired - Lifetime DE69334145D1 (de) 1992-08-03 1993-08-03 Terfenadin-Carboxylat und die Behandlung von Hautreizung
DE1993918584 Pending DE701443T1 (de) 1992-08-03 1993-08-03 Terfanadin Metaboliten und deren optische reine Isomeren zur Behandlung vonallegischen Krankheiten
DE19939320925 Expired - Lifetime DE9320925U1 (de) 1992-08-03 1993-08-03 Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen
DE1993634008 Expired - Lifetime DE69334008T2 (de) 1992-08-03 1993-08-03 Terfenadin-Carboxylat und die Behandlung von allergischen Erkrankungen
DE1993616660 Expired - Lifetime DE69316660T3 (de) 1992-08-03 1993-08-03 Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten
DE1993634008 Expired - Lifetime DE69334008D1 (de) 1992-08-03 1993-08-03 Terfenadin-Carboxylat und die Behandlung von allergischen Erkrankungen
DE1993634145 Expired - Lifetime DE69334145T2 (de) 1992-08-03 1993-08-03 Terfenadincarboxylat und die Behandlung von Hautreizung

Family Applications Before (5)

Application Number Title Priority Date Filing Date
DE1993616660 Expired - Lifetime DE69316660D1 (de) 1992-08-03 1993-08-03 Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten
DE1993634145 Expired - Lifetime DE69334145D1 (de) 1992-08-03 1993-08-03 Terfenadin-Carboxylat und die Behandlung von Hautreizung
DE1993918584 Pending DE701443T1 (de) 1992-08-03 1993-08-03 Terfanadin Metaboliten und deren optische reine Isomeren zur Behandlung vonallegischen Krankheiten
DE19939320925 Expired - Lifetime DE9320925U1 (de) 1992-08-03 1993-08-03 Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen
DE1993634008 Expired - Lifetime DE69334008T2 (de) 1992-08-03 1993-08-03 Terfenadin-Carboxylat und die Behandlung von allergischen Erkrankungen

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE1993634008 Expired - Lifetime DE69334008D1 (de) 1992-08-03 1993-08-03 Terfenadin-Carboxylat und die Behandlung von allergischen Erkrankungen
DE1993634145 Expired - Lifetime DE69334145T2 (de) 1992-08-03 1993-08-03 Terfenadincarboxylat und die Behandlung von Hautreizung

Country Status (11)

Country Link
US (1) US5375693A (de)
EP (4) EP0701443B2 (de)
JP (6) JP3041954B2 (de)
CA (1) CA2141572C (de)
DE (8) DE69316660D1 (de)
DK (3) DK1214937T3 (de)
ES (3) ES2086270T5 (de)
FI (1) FI950467A (de)
GB (1) GB2284351B (de)
RU (1) RU2167657C2 (de)
WO (1) WO1994003170A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69316660D1 (de) * 1992-08-03 1998-02-26 Sepracor Inc Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten
KR100387348B1 (ko) * 1993-06-24 2003-06-12 알바니 몰레큘라 리써치, 인크. 피페리딘 유도체의 제조 방법
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate
DK0766668T3 (da) 1994-05-18 2002-10-28 Aventis Pharma Inc Fremgangsmåde til fremstilling af vandfrie og hydratformer af som antihistaminer anvendelige piperidinderivater, polymorfer og pseudo-morfer deraf
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US5455049A (en) * 1995-01-04 1995-10-03 Ascent Pharmaceuticals, Inc. Terfenadine oral powder
JP4105762B2 (ja) * 1995-02-28 2008-06-25 アベンティス・ファーマスーティカルズ・インコーポレイテツド ピペリジノアルカノール化合物のための医薬組成物
GB9513972D0 (en) * 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
US5906747A (en) * 1995-11-13 1999-05-25 Biosepra Inc. Separation of molecules from dilute solutions using composite chromatography media having high dynamic sorptive capacity at high flow rates
US5922736A (en) 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US6201124B1 (en) 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6153754A (en) 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US5733756A (en) * 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
ES2124167B1 (es) * 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
US5925761A (en) * 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
DE69814086T2 (de) * 1997-08-26 2004-04-08 Aventis Pharmaceuticals Inc. Arzneimittel für die kombination piperidinoalkanol-dekongestivum
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
DE19913862C2 (de) * 1999-03-26 2003-04-10 Forschungszentrum Juelich Gmbh Verfahren zur biokatalysierten Umsetzung schlecht wasserlöslicher Substanzen
US20020007068A1 (en) 1999-07-16 2002-01-17 D'ambra Thomas E. Piperidine derivatives and process for their production
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
US6613907B2 (en) 2000-11-08 2003-09-02 Amr Technology, Inc. Process for the production of piperidine derivatives with microorganisms
KR20040012747A (ko) * 2001-04-09 2004-02-11 테바 파마슈티컬 인더스트리즈 리미티드 펙소페나딘 염산염의 다형체
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
WO2003020274A1 (en) * 2001-08-30 2003-03-13 Aventis Pharmaceuticals Inc. Treatment of atopic dermatitis
US20040044038A1 (en) * 2002-06-10 2004-03-04 Barnaba Krochmal Polymorphic form XVI of fexofenadine hydrochloride
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
JP2007508391A (ja) 2003-10-15 2007-04-05 コンビナトアールエックス インコーポレーティッド 免疫炎症性障害の治療のための方法および試薬
JP4515121B2 (ja) 2004-03-15 2010-07-28 東芝テック株式会社 ワイヤドットプリンタヘッド及びワイヤドットプリンタ
JP4473021B2 (ja) 2004-03-22 2010-06-02 東芝テック株式会社 窒化層形成方法、磁気回路形成部材、アーマチュア、ワイヤドットプリンタヘッド及びワイヤドットプリンタ
KR20070007196A (ko) * 2004-04-26 2007-01-12 테바 파마슈티컬 인더스트리즈 리미티드 펙소페나딘 히드로클로라이드의 결정형 및 이의 제조 방법
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
US7498443B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of carebastine
US7498345B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of piperidine derivatives
JP2008514641A (ja) * 2004-09-28 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド 結晶形フェキソフェナジン、およびその調製方法
WO2006063256A3 (en) * 2004-12-09 2007-03-29 Celgene Corp Treatment using d-threo methylphenidate
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
ES2534345T3 (es) * 2007-04-13 2015-04-21 Southern Research Institute Bitionol como agente antiangiogénico
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
WO2014052836A3 (en) 2012-09-27 2014-05-22 University Of Rochester Methods and compositions for treating infection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US880801A (en) 1908-03-03 Harold Larsen Vibrator.
US922890A (en) 1907-03-26 1909-05-25 Peder Joergen Hansen Stream-motor.
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4552899B1 (de) 1984-04-09 1992-10-20 Analgesic Associates
US4829064A (en) 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
US4996061A (en) 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
WO1993021156A1 (en) * 1992-04-10 1993-10-28 Merrell Dow Pharmaceuticals Inc. 4-diphenylmethyl piperidine derivatives and process for their preparation
DK0639976T3 (da) 1992-05-11 1999-02-15 Merrell Pharma Inc Anvendelse af terfenadin-derivater som antihistaminika i patienter med leversygdomme
DE69316660D1 (de) * 1992-08-03 1998-02-26 Sepracor Inc Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten
KR100387348B1 (ko) * 1993-06-24 2003-06-12 알바니 몰레큘라 리써치, 인크. 피페리딘 유도체의 제조 방법
EP1953142A1 (de) * 1993-06-25 2008-08-06 Aventis Inc. Neuartige Zwischenprodukte zur Herstellung antihistaminischer 4-Diphenylmethyl-/Diphenylmethoxy-Piperidinderivate
CA2128821A1 (en) * 1993-07-27 1995-01-28 Dilip J. Gole Freeze-dried pharmaceutical dosage form and process for separation thereof
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate

Also Published As

Publication number Publication date Type
RU95107881A (ru) 1996-11-27 application
FI950467A0 (fi) 1995-02-02 application
EP1214937A2 (de) 2002-06-19 application
JP3288660B2 (ja) 2002-06-04 grant
EP0815860B1 (de) 2006-04-12 grant
JP2000086512A (ja) 2000-03-28 application
DK0815860T3 (da) 2006-08-14 grant
DE701443T1 (de) 1997-01-30 grant
DE69316660T2 (de) 1998-05-07 grant
GB2284351B (en) 1996-11-27 grant
DE69334145T2 (de) 2008-01-24 grant
JP3041954B2 (ja) 2000-05-15 grant
DE69334008T2 (de) 2006-10-19 grant
JPH08500348A (ja) 1996-01-16 application
WO1994003170A1 (en) 1994-02-17 application
EP0815860A3 (de) 1998-01-14 application
DE69334008D1 (de) 2006-05-24 grant
EP0701443B2 (de) 2000-11-22 grant
ES2257757T3 (es) 2006-08-01 grant
JP2000086513A (ja) 2000-03-28 application
JP3037697B2 (ja) 2000-04-24 grant
JP2000086515A (ja) 2000-03-28 application
RU2167657C2 (ru) 2001-05-27 grant
ES2284740T3 (es) 2007-11-16 grant
EP0701443A1 (de) 1996-03-20 application
GB9502183D0 (en) 1995-03-22 grant
DK0701443T3 (da) 1998-02-09 grant
JP2000086514A (ja) 2000-03-28 application
ES2086270T3 (es) 1998-03-01 grant
EP1214937B1 (de) 2007-05-30 grant
DK701443T4 (de) grant
DK0701443T4 (da) 2000-12-18 grant
EP1688142A1 (de) 2006-08-09 application
EP0701443B1 (de) 1998-01-21 grant
FI950467A (fi) 1995-03-31 application
DE9320925U1 (de) 1995-08-31 grant
DK701443T3 (de) grant
EP1214937A3 (de) 2002-10-30 application
US5375693A (en) 1994-12-27 grant
JP3288661B2 (ja) 2002-06-04 grant
JP3288662B2 (ja) 2002-06-04 grant
CA2141572A1 (en) 1994-02-17 application
DE69334145D1 (de) 2007-07-12 grant
DK1214937T3 (da) 2007-09-17 grant
ES2086270T1 (es) 1996-07-01 application
FI950467D0 (de) grant
EP0815860A2 (de) 1998-01-07 application
ES2086270T5 (es) 2001-02-01 grant
GB2284351A (en) 1995-06-07 application
JP2000086516A (ja) 2000-03-28 application
DE69316660D1 (de) 1998-02-26 grant
CA2141572C (en) 2001-02-06 grant

Similar Documents

Publication Publication Date Title
DE68928665T2 (de) Behandlung von gastro-intestinalen krankheiten
DE9320785U1 (de) Gerät zur kontrollierten Zudosierung von NO zur Atemluft von Patienten
DE69120933T2 (de) Topische Anwendung von Glycosaminoglykane zur Prävention und Behandlung der Zervikal- oder Vaginalerkrankungen
DE69600730T2 (de) Instrument zum rausziehen von zecken aus der menschlichen oder tierischen haut
DE68927667T2 (de) Therapeutische Behandlung von Säugetieren
DE69230772T2 (de) Arzneizubereitungen zur Behandlung von Onychomykosen
DE69326014T2 (de) Dithiocarbamate zur behandlung von atheroskerosis und weiteren kardiovasculären und entzündlichen erkrankungen
DE69405051T2 (de) Decantierzentrifuge zur Behandlung von nuklearen Produkten
DE68910175T2 (de) Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut.
DE69232497T2 (de) Behandlung von krankheiten durch ortsspezifische instillation von zellen oder ortsspezifische transformation von zellen sowie ausrüstung dafür
DE3425466A1 (de) Synergistisches arzneimittelpraeparat zur behandlung von leberkrankheiten
RU93052163A (ru) (s) - (+) - гидроксихлорохин и композиция для лечения
DE9318429U1 (de) Mittel zur Abwehr und/oder Behandlung von Insektenstichen
DE69333073D1 (de) Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen
DE68929077T2 (de) Transplantieren von genetisch modifizierten zellen zur behandlung von krankheiten des zentralen nervensystems
DK0602961T3 (da) Hudbehandlingssammensætning af lanolin/lanolinsyreestere
DE68921209T2 (de) Zusammensetzungen und verfahren zur behandlung von hautkrankheiten und zur aktivierung der wundheilung.
DE69228949T2 (de) Tgf-beta zur verbesserung der regeneration von neuronalem gewebe
DE69230733D1 (de) Teil der konstanten region von ige enthaltender impfstoff zur behandlung ige-induzierter allergischer reaktionen
DE69427116T2 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
FI953899A (fi) Substituoituja atsolonijohdannaisia Helicobacterin aiheuttamien sairauksien hoitamiseksi
RU97114848A (ru) Лекарственная форма для выделения коллагеназы в ранах и способ ее получения
DE68928752T2 (de) Zubereitungen zur verwendung bei der behandlung von psoriasis und von neuropsychiatrischen krankheiten
NL300380I2 (nl) Gesubstitueerde pyrazolylbenzeensulfonamiden voor de behandeling van onstekingen
FI931460A0 (fi) Behandling av filtrat fraon blekeri